Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases

被引：0
|
作者：
Mei-Chuan Lee
Chia-Te Liao
Han Siong Toh
Chih-Chen Chou
Wei-Ting Chang
Zhih-Cherng Chen
Wen-Shiann Wu
Tsung Yu
Carol Strong
机构：
[1] Department of Pharmacy,Department of Public Health, College of Medicine
[2] Chi Mei Medical Center,Institute of Clinical Medicine
[3] National Cheng Kung University,Department of Statistics, College of Management
[4] Division of Cardiology,Department of Biotechnology
[5] Department of Internal Medicine,Department of Pharmacy
[6] Chi Mei Medical Center,undefined
[7] Department of Intensive Care Medicine,undefined
[8] Chi Mei Medical Center,undefined
[9] National Cheng Kung University,undefined
[10] Division of Infectious Diseases,undefined
[11] Department of Internal Medicine,undefined
[12] Kaohsiung Veterans General Hospital,undefined
[13] National Cheng Kung University,undefined
[14] Southern Taiwan University of Science and Technology,undefined
[15] Chia-Nan University of Pharmacy and Science,undefined
来源：
Cardiovascular Drugs and Therapy | 2021年 / 35卷
关键词：
Cost-effectiveness; Rivaroxaban; Cardiovascular diseases; Coronary artery diseases; Secondary prevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：539 / 547
页数：8
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases
    Lee, Mei-Chuan
    Liao, Chia-Te
    Toh, Han Siong
    Chou, Chih-Chen
    Chang, Wei-Ting
    Chen, Zhih-Cherng
    Wu, Wen-Shiann
    Yu, Tsung
    Strong, Carol
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (03) : 539 - 547
  • [2] Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
    Ferrara, Pietro
    Cortesi, Paolo A.
    Di Laura, Danilo
    Maggioni, Aldo P.
    Mantovani, Lorenzo G.
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (05) : 459 - 468
  • [3] Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
    Pietro Ferrara
    Paolo A. Cortesi
    Danilo Di Laura
    Aldo P. Maggioni
    Lorenzo G. Mantovani
    [J]. Clinical Drug Investigation, 2021, 41 : 459 - 468
  • [4] Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial
    Chen, Jersey
    Bhatt, Deepak L.
    Dunn, Elizabeth Schneider
    Shi, Chunxue
    Caro, J. Jaime
    Mahoney, Elizabeth M.
    Gabriel, Sylvie
    Jackson, Joseph D.
    Topol, Eric J.
    Cohen, David J.
    [J]. VALUE IN HEALTH, 2009, 12 (06) : 872 - 879
  • [5] Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone
    Rothberg, M
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (06) : 464 - 464
  • [6] Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
    Rawal, Shalin
    Sharma, Kamal
    Shah, Aditya
    Bavishi, Shriya
    Christian, Cleris
    Bhatt, Parjanya
    Konat, Ashwati
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [7] Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
    Petersohn, Svenja
    Pouwels, Xavier
    Ramaekers, Bram
    ten Cate-Hoek, Arina
    Joore, Manuela
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (13) : 1354 - 1365
  • [8] Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective
    Ademi, Zanfina
    Zomer, Ella
    Tonkin, Andrew
    Liew, Danny
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 270 : 54 - 59
  • [9] COST-EFFECTIVENESS OF RIVAROXABAN AND ASPIRIN COMPARED TO ASPIRIN ALONE IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE: AN AUSTRALIAN PERSPECTIVE
    Ademi, Z.
    Zomer, E.
    Tonkin, A.
    Liew, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [10] The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective
    Andre Lamy
    John Eikelboom
    Wesley Tong
    Fei Yuan
    Shrikant I. Bangdiwala
    Jackie Bosch
    Stuart Connolly
    Eva Lonn
    Gilles R. Dagenais
    Kelley R. H. Branch
    Wei-Jhih Wang
    Deepak L. Bhatt
    Jeffrey Probstfield
    Georg Ertl
    Stefan Störk
    P. Gabriel Steg
    Victor Aboyans
    Isabelle Durand-Zaleski
    Lars Ryden
    Salim Yusuf
    [J]. American Journal of Cardiovascular Drugs, 2024, 24 : 117 - 127
12345